Press release
Myocardial Infarction Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Myocardial Infarction Treatment Landscape @ Myocardial Infarction Pipeline Outlook [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myocardial Infarction Pipeline Report
* On 19 August 2025, Boehringer Ingelheim conducted a study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack.
* DelveInsight's Myocardial Infarction pipeline report depicts a robust space with 30+ active players working to develop 40+ pipeline therapies for Myocardial Infarction treatment.
* The leading Myocardial Infarction Companies such as Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
* Promising Myocardial Infarction Pipeline Therapies such as Ilomedin, MiSaver Registered , BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, and others.
Stay informed about the cutting-edge advancements in Myocardial Infarction treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Myocardial Infarction Clinical Trials Assessment [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myocardial Infarction Emerging Drugs Profile
* FDY 5301: Faraday Pharmaceuticals
FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are uniquely well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. Currently, the drug is in Phase III stage of its clinical trial for the treatment AMI.
* Glenzocimab: Acticor Biotech
Glenzocimab is a humanized monoclonal antibody fragment designed to target the human platelet glycoprotein VI (GPVI), which plays a crucial role in thrombus formation and stability. Its mechanism of action involves inhibiting platelet activation and aggregation, particularly in the context of ischemic stroke and myocardial infarction. Currently, it is in Phase II stage of its clinical trial for the treatment of myocardial infarction.
* BI765845: Boehringer Ingelheim
BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ischemic conditions by improving oxygen supply and reducing oxygen demand in affected tissues. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myocardial infarction.
The Myocardial Infarction Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Myocardial Infarction with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.
* Myocardial Infarction Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myocardial Infarction market.
Learn more about Myocardial Infarction Drugs opportunities in our groundbreaking Myocardial Infarction research and development projects @ Myocardial Infarction Unmet Needs [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myocardial Infarction Companies
Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
Myocardial Infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Myocardial Infarction Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Stay informed about how we're transforming the future of Cardiovascular Diseases @ Myocardial Infarction Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myocardial Infarction Pipeline Report
* Coverage- Global
* Myocardial Infarction Companies- Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
* Myocardial Infarction Pipeline Therapies- Ilomedin, MiSaver Registered , BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, and others.
* Myocardial Infarction Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myocardial Infarction Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Myocardial Infarction Pipeline on our website @ Myocardial Infarction Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Myocardial Infarction: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myocardial Infarction - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* FDY 5301: Faraday Pharmaceuticals
* Mid Stage Products (Phase II)
* Glenzocimab: Acticor Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* Preclinical Stage Products
* Drug Name: Company Name
* Inactive Products
* Myocardial Infarction - Collaborations Assessment- Licensing / Partnering / Funding
* Myocardial Infarction - Unmet Needs
* Myocardial Infarction - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myocardial-infarction-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myocardial Infarction Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4156681 • Views: …
More Releases from ABNewswire
Phenylketonuria Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
elveInsight's, "Phenylketonuria Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Phenylketonuria pipeline landscape. It covers the Phenylketonuria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Phenylketonuria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Phenylketonuria…
The U.S.A. Is a R.I.C.O by Patrick Farrell Goes Global - A Bold Call for Truth, …
The release of The U.S.A. Is a R.I.C.O: Racketeering Influenced Corrupt Organization, by author and activist Patrick Farrell, is igniting global discussions on freedom, health, and financial independence. Now available through Barnes & Noble, Waterstones, Chapters/Indigo, Walmart, Amazon, and other major platforms, this groundbreaking book dives deep into the hidden systems shaping American life and offers readers the knowledge to reclaim control over their physical, financial, and spiritual well-being.
Farrell takes…
Understanding DUI Testing: Barton DUI Law Breaks Down Breathalyzer and Field Tes …
Barton DUI Law releases a comprehensive breakdown of DUI testing, clarifying how breathalyzer and field sobriety tests work and exposing their limitations. From calibration requirements to error-prone subjective evaluations, the guide helps Georgia drivers better understand and challenge DUI evidence. Learn more at bartonduilaw.com.
Stockbridge, GA - August 22, 2025 - Barton DUI Law, a leading DUI defense firm in Georgia, today announces the release of a new in-depth guide designed…
Stability First: How Lubbock Property Management Is Keeping Rentals Occupied
Image: https://www.abnewswire.com/upload/2025/08/5fcc1c5b9b8cc4319b61d40541998d10.jpg
Lubbock, TX - August 22, 2025 - With steady growth reshaping West Texas, Coldwell Banker Residential Property Management [https://cblubbockleasing.com] is highlighting housing stability as a defining challenge for the city's rental market. Texas Tech University now enrolls more than 41,000 students, and the U.S. Census Bureau projects nearly 6% population growth from 2020 to 2025. In this environment, professional Lubbock property management has become essential for reducing turnover, protecting…
More Releases for Myocardial
Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Numb …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual…
Diabetes Epidemic Fuels Myocardial Ischemia Market Growth: An Emerging Driver Tr …
The Myocardial Ischemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Myocardial Ischemia Market?
The myocardial ischemia market has grown strongly. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a CAGR of 7.3%.…
Transforming the Myocardial Ischemia Market in 2025: Diabetes Epidemic Fuels Myo …
What Is the Expected Size and Growth Rate of the Myocardial Ischemia Market?
The market size for myocardial ischemia has demonstrated considerable growth over the last few years. There's a predicted growth from $0.79 billion in 2024 to $0.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historical period can be credited to the use of telemedicine and remote monitoring, the discovery…
Myocardial Infarction Treatment Market Growth and Insights 2024
"The Business Research Company recently released a comprehensive report on the Global Myocardial Infarction Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, Î' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026".
The Global market size of Myocardial Infarction Drugs Market was $XX…
Myocardial Ischemia - Pipeline Review, H1 2017 - Pharmaceutical Report
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm…
